Allarity Therapeutics (ALLR) Projected to Post Quarterly Earnings on Friday

Allarity Therapeutics (NASDAQ:ALLR) is projected to issue its results before the market opens on Friday, November 13th. Analysts expect Allarity Therapeutics to post earnings of ($0.21) per share for the quarter.

Allarity Therapeutics (NASDAQ:ALLR) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.25) by $0.04. On average, analysts expect Allarity Therapeutics to post ($0.80) EPS for the current fiscal year and ($0.86) EPS for the next fiscal year.

Allarity Therapeutics Price Performance

Shares of ALLR stock opened at $0.94 on Thursday. Allarity Therapeutics has a 52-week low of $0.77 and a 52-week high of $1.84. The stock has a 50 day moving average price of $1.03 and a 200 day moving average price of $1.21.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Thursday, October 15th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $10.25.

Allarity Therapeutics Company Profile

Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biotechnology company focused on developing personalized treatments for cancer. The company uses its Drug Response Predictor (DRP) technology to analyze patient and tumor characteristics and identify individuals who may be more likely to respond to specific drug candidates. Allarity’s development programs have included stenoparib, also known as 2X-121, an orally administered PARP inhibitor being investigated for potential use in oncology.